Aerosol Deposition from Heraeus Accelerates Development of Antiseptic Coatings

Heraeus reports EOS Biomaterials Incorporated relies on Heraeus R&D equipment to develop coatings for the medical market. The company’s technology can be used for surgical implants and wound treatment.

Their patented coatings include antiseptic and antibiotic effects and enable a slow-release of antibiotics. The powder formulations can be applied with the aerosol deposition method. “With our own aerosol deposition machine, we will be able to test and optimize new materials and material combinations in even shorter cycles in the future,” says Mr. Lee, Chairman of EOS Biomaterials Incorporated.

There are numerous fields of application for antiseptic coatings in medical technology. For example, they can be applied on implants or medical instruments. They are usually made from an active metallic component – for example silver – and a carrier material such as ceramic. The larger the active surface, the higher the antiseptic effect. However, the right material ratio of active component and carrier material not only determines whether the coatings achieve the desired antiseptic effect.

The raw material metal is also a cost driver. That’s why manufacturers strive to identify the best mixing ratio. “We already draw on Heraeus‘ materials expertise as part of a development contract. Our medical coatings experts receive powder development support with testing, analysis and consulting,” so Mr. Lee.

The equipment is built in Germany and shipped to EOS Biomaterials in New Taipei City. It allows coating of areas up to 300x50mm2 and axially symmetric items. “The robustness of equipment and process makes aerosol deposition the ideal match for EOS Biomaterials´ development goals,” says Ilka Luck, Head of Heraeus High Performance Coatings. “They are working on very innovative products, and we are very happy to support them in this effort.”

Why Aerosol Deposition?

In order to develop new coatings quickly, the method used needed to be as flexible and easy to handle as possible. However, most coating methods require high temperatures and are carried out under high vacuum. Aerosol Deposition, on the other hand, is carried out at room temperature and requires only rough vacuum. Also, no materials hazardous to health are used, which simplifies handling.

The high-performance coatings must not peel off from their substrate. The particularly good adhesion, in turn, is one of the outstanding properties of coatings produced with aerosol deposition. This is due to the fact that the substrate and the coating form a chemical bond where they meet.

With other coating methods, the materials used must be heated or vaporized. These temperatures can cause changes in the material and thus in the material properties. In contrast, aerosol deposition takes place at room temperature. During deposition on the substrate, neither a chemical reaction nor a phase transformation occurs. Thus, the properties of the starting material are largely retained in the coating.

This is not the only challenge that aerosol deposition does not present in the first place. When several materials are combined, it increases the complexity of the coating process. The components – in this case metal and ceramic – often have very different properties. Due to different melting points, for example, they cannot be applied simultaneously using conventional methods, or only with great effort. Aerosol deposition allows coatings with any material and combinations of materials. The only requirement is that they are available as powder.

SourceHeraeus

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”